Logo for Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Investor Relations Material

Latest events

Logo for Anebulo Pharmaceuticals

Q2 2024

13 Feb, 2024
Logo for Anebulo Pharmaceuticals

Q1 2024

14 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Anebulo Pharmaceuticals Inc

Access all reports
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase 2 clinical trial to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.